Sveriges mest populära poddar

Multiple Myeloma | Oncology Today with Dr Neil Love: Emerging Role of CELMoDs (Cereblon E3 Ligase Modulators) and Other Novel Approaches to Targeting Protein Degradation Pathways in Multiple Myeloma

39 min•28 september 2023

Featuring an interview with Dr Paul G Richardson, including the following topics:

Biologic rationale for targeting protein degradation pathways as a therapeutic approach in multiple myeloma (MM); mechanism of action of CELMoDs (0:00)
Similarities and differences between iberdomide, mezigdomide and standard immunomodulatory drugs (7:14)
Compassionate use of melflufen and belantamab mafodotin (12:08)
Current management strategies for newly diagnosed MM (16:30)
DETERMINATION: Evaluation of trial findings on racial and ethnic disparities and differential outcomes (23:02)
Tailoring of up-front daratumumab-based therapies; management of extramedullary disease (33:17)

CME information and select publications

Fler avsnitt av Research To Practice | Oncology Videos

Oral SERDs for Breast Cancer | Erica Mayer, MD, MPH, FASCO

30 apr.•29 min

Oral SERDs for Breast Cancer | Aditya Bardia, MD, MPH

30 apr.•28 min

EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances

27 apr.•57 min

EGFR-Mutant Non-Small Cell Lung Cancer | Suresh S Ramalingam, MD

27 apr.•26 min

EGFR-Mutant Non-Small Cell Lung Cancer | Helena Yu, MD

27 apr.•30 min

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium

25 apr.•17 min

Prostate Cancer — Year in Review Series on Relevant New Datasets and Advances

23 apr.•58 min

Prostate Cancer | Scott T Tagawa, MD, MS

23 apr.•25 min

Prostate Cancer | Andrew J Armstrong, MD, ScM

23 apr.•24 min

Menin Inhibitors in Acute Myeloid Leukemia — Year in Review Series on Relevant New Datasets and Advances

20 apr.•59 min

Research To Practice | Oncology Videos med Dr Neil Love finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.